Key result
Cardiac comorbidity was associated with a 7.5-fold higher risk of targeted therapy-related cardiotoxicity compared to other comorbidities (7.5% vs. 1.0%) in patients with stage-IV non-small cell lung cancer.
Why the study?
Understanding of how cardiac comorbidity and toxicity affect clinical outcomes in patients with advanced NSCLC following targeted therapy remains limited.
Does preexisting cardiac comorbidity increase the risk of targeted therapy-associated cardiotoxicity and affect survival in patients with stage-IV NSCLC?
Population
701 patients with stage-IV NSCLC treated with targeted therapy
Comparison
Cardiac vs other vs no comorbidities
Design
14-year prospective cohort study
Authors
Loading...
May warrant closer cardiotoxicity monitoring in stage-IV NSCLC patients with cardiac comorbidity on targeted therapy; leaves open prospective validation and survival effects.
Cohort (n=701)
No
Does preexisting cardiac comorbidity increase the risk of targeted therapy-associated cardiotoxicity and affect survival in patients with stage-IV NSCLC?
Relative Risk: 7.5
Absolute Event Rate: 7.5% vs 1%
p-value: p=<0.001
In patients with stage-IV NSCLC, preexisting cardiac comorbidities significantly increase the risk of targeted therapy-associated cardiotoxicity, though overall cardiotoxicity incidence remains low.
Peng et al. (2024) conducted a cohort in Stage-IV non-small cell lung cancer (n=701). Cardiac comorbidity vs. Other comorbidities was evaluated on Targeted therapy-related cardiotoxicity (7.5-fold higher risk, p=<0.001). Cardiac comorbidity was associated with a 7.5-fold higher risk of targeted therapy-related cardiotoxicity compared to other comorbidities (7.5% vs. 1.0%) in patients with stage-IV non-small cell lung cancer.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: